This trial was designed to answer the question that ultimately matters: does sustained NAD+ augmentation translate into meaningful clinical benefit for people with PD?”, explains senior author Charalampos Tzoulis. The multicenter, randomized, placebo-controlled trial assigned 410 participants with early PD to receive twice-daily oral nicotinamide riboside or placebo for 1 year. The primary endpoint was change from baseline in self-reported motor and nonmotor symptoms, measured using the MDS-Unified Parkinson’s Disease Rating Scale.
Secondary and exploratory outcomes included several predefined clinical criteria, dopamine transporter imaging as a biomarker of PD progression, and metabolic analysis of NAD+ levels. This is a preview of subscription content, access via your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription Receive 12 digital issues and online access to articles Prices may be subject to local taxes which are calculated during checkout Nature Aging https://www.nature.com/nataging Attwaters, M. NAD+ precursor fails in Parkinson’s disease.
Nat Aging (2026). https://doi.org/10.1038/s43587-026-01277-x DOI: https://doi.org/10.1038/s43587-026-01277-x
Extract — continue reading at the source.
